V
4.21
0.03 (0.76%)
| Previous Close | 4.18 |
| Open | 4.26 |
| Volume | 26,294 |
| Avg. Volume (3M) | 190,047 |
| Market Cap | 39,783,688 |
| Price / Sales | 1.91 |
| Price / Book | 238.54 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -236.41% |
| Diluted EPS (TTM) | -11.40 |
| Quarterly Revenue Growth (YOY) | -10.10% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | -53.66 M |
| Levered Free Cash Flow (TTM) | -32.56 M |
| Return on Assets (TTM) | -62.87% |
| Return on Equity (TTM) | -1,546.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Verrica Pharmaceuticals Inc. | Mixed | Bearish |
AIStockmoo Score
2.0
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 44.90% |
| % Held by Institutions | 32.25% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KIRBY JOHN J. | 5.12 | - | 3,536 | 18,104 |
| MANNING PAUL B | 5.12 | - | 4,126,142 | 21,125,847 |
| RIEGER JAYSON | 5.12 | - | 94,311 | 482,872 |
| ROSENBERG NOAH L. | 5.12 | - | 2,357 | 12,068 |
| ZAWITZ DAVID | 5.12 | - | 10,000 | 51,200 |
| Aggregate Net Quantity | 4,236,346 | |||
| Aggregate Net Value ($) | 21,690,092 | |||
| Aggregate Avg. Buy ($) | 5.12 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KIRBY JOHN J. | Officer | 25 Nov 2025 | Buy (+) | 3,536 | 5.12 | 18,104 |
| RIEGER JAYSON | Officer | 25 Nov 2025 | Buy (+) | 94,311 | 5.12 | 482,872 |
| MANNING PAUL B | Director | 25 Nov 2025 | Buy (+) | 1,375,380 | 5.12 | 7,041,946 |
| MANNING PAUL B | Director | 25 Nov 2025 | Buy (+) | 2,750,762 | 5.12 | 14,083,901 |
| ZAWITZ DAVID | Officer | 25 Nov 2025 | Buy (+) | 10,000 | 5.12 | 51,200 |
| ROSENBERG NOAH L. | Officer | 25 Nov 2025 | Buy (+) | 2,357 | 5.12 | 12,068 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |